Drug License in India

A drug license in India is a statutory approval issued under the Drugs and Cosmetics Act, 1940, authorising the holder to manufacture, sell, distribute, import, or export drugs and pharmaceutical products. Any person or business entity engaged in these activities, including pharmaceutical manufacturers, wholesale drug license holders, retail chemists, importers, and contract manufacturers, must obtain the relevant drug licence before commencing operations.

Drug licence approval timelines in India vary by licence category, state regulator, application completeness, and inspection requirements. Clean applications are commonly processed within 30-90 working days, while complex manufacturing licences or deficiency queries may extend the approval timeline.

A drug manufacturing license requires the applicant to have an approved manufacturing facility meeting GMP and Schedule M standards, qualified technical staff including a competent person or pharmacist, validated equipment and utilities, a documented quality management system, and approved SOPs. The facility is subject to inspection by Drug Inspectors before the pharmaceutical license in India is granted. Product-specific dossiers may also be required depending on the drug category.

A wholesale drug license, issued under Forms 20B and 21B, authorises the holder to purchase drugs from manufacturers or importers and sell them to other licenced dealers, hospitals, or institutions. A retail drug license, issued under Forms 20 and 21, authorises a retail chemist or pharmacy to sell drugs directly to consumers. It requires a registered pharmacist on the premises of retailers and appropriate storage infrastructure, and compliance with schedule drug handling norms under the Drugs and Cosmetics Act for both retailers and wholesalers.

Yes. Most categories of drug license in India are issued for a fixed validity period and must be renewed before expiry to remain operative. Drug manufacturing license renewals are typically due every five years, while wholesale drug license and retail drug license approvals are renewed annually in most states. Failure to renew on time results in the licence lapsing, which constitutes unauthorised operation under the Drugs and Cosmetics Act and exposes the business to legal action.

Yes. Existing pharmaceutical license in India holders can apply for amendment of their licence to include additional drug products, dosage forms, or manufacturing lines. The amendment process requires updated documentation, possible re-inspection of the facility, and approval from the State Drug Controller or CDSCO depending on the nature of the change. Additions that involve new drug substances or novel formulations may require a separate CDSCO drug license or new drug approval filing.

A loan licence is a drug manufacturing license variant that allows a business to manufacture drugs at the facility of another licenced manufacturer, without owning a manufacturing unit. The loan licensee is responsible for quality standards, labelling, and regulatory compliance, while the actual production is carried out at the lending manufacturer's facility. This arrangement is particularly useful for businesses launching new formulations or seeking to expand capacity without capital investment in a new plant, and requires appropriate documentation and drug license registration under the Drugs and Cosmetics Rules.

Sugam is the online portal developed by CDSCO for digital submission and processing of drug license applications at the central level, including import licences, new drug approvals, clinical trial permissions, and medical device registrations. It enables drug license registration filing, document upload, fee payment, and application status tracking. State drug licence applications, including wholesale drug license and drug manufacturing license, are filed through the respective state portals or in physical form depending on the state.

Manufacturing, selling, distributing, or importing drugs without a valid drug license in India is a cognisable offence under the Drugs and Cosmetics Act, 1940. It can result in imprisonment of up to three years, financial penalties, product seizure, cancellation of business registration, and permanent blacklisting from future pharma regulatory approval processes. Drug Inspectors are empowered to carry out surprise inspections, seal premises, and initiate prosecution without prior notice.

IMARC Engineering provides end-to-end drug license consultancy, from licence category identification and facility gap assessment to documentation preparation, drug license registration filing, inspection readiness, and post-approval compliance. Our team supports drug manufacturing license applications, CDSCO drug license submissions, wholesale drug license and retail drug license filings, and pharma regulatory approval processes across all drug licence categories.